Study identifier:M/100977/25
ClinicalTrials.gov identifier:NCT01425814
EudraCT identifier:N/A
CTIS identifier:N/A
A phase IIa, randomised, single dose, double-blind, double-dummy, 6 way complete cross-over, placebo controlled clinical trial to assess the efficacy, safety and tolerability of 4 strengths of LAS100977 QD compared to placebo and an active comparator in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD)
Phase 2
No
LAS100977, Reference, Placebo
All
87
Interventional
40 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Feb 2017 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Arm #2 Single dose, double blind treatment period | Drug: LAS100977 Dry powder inhalation,Once daily, single dose |
Experimental: Arm #3 Single dose, double blind treatment period | Drug: LAS100977 Dry powder inhalation,Once daily, single dose |
Experimental: Arm #4 Single dose, double blind treatment period | Drug: LAS100977 Dry powder inhalation,Once daily, single dose |
Active Comparator: Arm #5 Single dose, double blind treatment period | Drug: Reference Dry powder inhalation (capsule),single dose |
Placebo Comparator: Arm #6 Single dose, double blind treatment period | Drug: Placebo Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose |
Experimental: Arm #1 Single dose, double blind treatment period | Drug: LAS100977 Dry powder inhalation,Once daily, single dose |